Open-label trial of imatinib in combination with vinorelbine for patients with advanced breast carcinoma: ICON.

Trial Profile

Open-label trial of imatinib in combination with vinorelbine for patients with advanced breast carcinoma: ICON.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Imatinib (Primary) ; Vinorelbine (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms ICON; INV181
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 10 Dec 2012 To date, 33 patients have been enrolled in the study. Recruitment for dose groups 1-3 is complete.
    • 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Apr 2012 Planned end date changed from 1 Dec 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top